HC Wainwright Issues Positive Outlook for SLN Earnings

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) – Research analysts at HC Wainwright raised their Q2 2026 earnings estimates for shares of Silence Therapeutics in a research note issued on Friday, May 8th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.36) for the quarter, up from their prior forecast of ($0.48). HC Wainwright has a “Buy” rating and a $75.00 price target on the stock. The consensus estimate for Silence Therapeutics’ current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Silence Therapeutics’ Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.38) EPS, FY2027 earnings at ($1.74) EPS, FY2028 earnings at ($1.65) EPS, FY2029 earnings at ($1.74) EPS and FY2030 earnings at ($1.77) EPS.

Silence Therapeutics (NASDAQ:SLN) last issued its earnings results on Thursday, May 7th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.14). Silence Therapeutics had a negative return on equity of 105.34% and a negative net margin of 8,943.86%.The business had revenue of $0.42 million during the quarter, compared to analysts’ expectations of $1.26 million.

Several other equities analysts also recently commented on SLN. Jefferies Financial Group raised shares of Silence Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 18th. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, March 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $55.00.

Silence Therapeutics Trading Up 2.9%

Shares of NASDAQ:SLN opened at $7.17 on Tuesday. The company has a market cap of $338.67 million, a price-to-earnings ratio of -4.51 and a beta of 1.52. The company has a 50-day moving average price of $6.47 and a 200-day moving average price of $6.15. Silence Therapeutics has a 12 month low of $3.69 and a 12 month high of $8.40.

Hedge Funds Weigh In On Silence Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Boothbay Fund Management LLC increased its position in shares of Silence Therapeutics by 1.0% during the second quarter. Boothbay Fund Management LLC now owns 252,421 shares of the company’s stock valued at $1,464,000 after buying an additional 2,409 shares during the period. Two Sigma Investments LP increased its position in shares of Silence Therapeutics by 6.6% during the third quarter. Two Sigma Investments LP now owns 63,247 shares of the company’s stock valued at $328,000 after buying an additional 3,935 shares during the period. ADAR1 Capital Management LLC increased its position in shares of Silence Therapeutics by 26.8% during the fourth quarter. ADAR1 Capital Management LLC now owns 23,643 shares of the company’s stock valued at $144,000 after buying an additional 5,000 shares during the period. China Universal Asset Management Co. Ltd. increased its position in shares of Silence Therapeutics by 65.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,653 shares of the company’s stock valued at $83,000 after buying an additional 5,421 shares during the period. Finally, Bank of Montreal Can increased its position in shares of Silence Therapeutics by 4.4% during the fourth quarter. Bank of Montreal Can now owns 160,474 shares of the company’s stock valued at $976,000 after buying an additional 6,692 shares during the period. Hedge funds and other institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.